Drug Trial Radar · NCT04254107
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
133
Actual
Start
May 29, 2020
Primary completion
Dec 1, 2023
Study completion Dec 1, 2023
Sponsor
- Lead sponsor
- Seagen Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).
Conditions
- Non-small Cell Lung Cancer
- Gastric Carcinoma
- Gastroesophageal Junction Carcinoma
- Classical Hodgkin Lymphoma
- Diffuse Large B-cell Lymphoma
- Peripheral T-cell Lymphoma
- Cutaneous Melanoma
- Head and Neck Squamous Cell Carcinoma
- Bladder Cancer
- Ovarian Cancer
- Triple Negative Breast Cancer
- Cervical Cancer
Interventions
SEA-TGTDrug
Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
sasanlimabDrug
Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
brentuximab vedotinDrug
Given by IV on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
- Number of participants with laboratory abnormalities by gradeTime frame: Through 45-52 days following last dose of SEA-TGT; up to approximately 3 years
- Number of participants with a dose-limiting toxicity (DLT) at each dose levelTime frame: Up to 21 days
Locations
36 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona
City of Hope
Duarte, California
California Research Institute
Los Angeles, California
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
San Francisco, California
Yale Cancer Center
New Haven, Connecticut
Johns Hopkins Medical Center
Baltimore, Maryland
Maryland Oncology Hematology, P.A.
Rockville, Maryland
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Minnesota Oncology Hematology P.A.
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
Weill Cornell Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Wake Forest Baptist Medical Center / Wake Forest University
Winston-Salem, North Carolina
University of Cincinnati Cancer Institute
Cincinnati, Ohio
Providence Portland Medical Center
Portland, Oregon
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Oncology - Austin Midtown
Austin, Texas
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas
MD Anderson Cancer Center / University of Texas
Houston, Texas
Texas Oncology - Northeast Texas
Tyler, Texas
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
Blacksburg, Virginia
Virginia Cancer Specialists, PC
Fairfax, Virginia
Carbone Cancer Center / University of Wisconsin
Madison, Wisconsin
University of Alberta / Cross Cancer Institute
Edmonton, Alberta, Canada
University Health Network, Princess Margaret Hospital
Toronto, Other, Canada
Institut Gustave Roussy
Villejuif, Other, France
Istituto Europeo di Oncologia
Milan, Other, Italy
Policlinico Universitario Agostino Gemelli
Rome, Other, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Other, Spain
L'Institut Catala d'Oncologia
L'Hospitalet de Llobregat, Other, Spain
HM Centro Integral Oncologico Clara Campal
Madrid, Other, Spain
Sarah Cannon Research Institute UK
London, Other, United Kingdom
The Royal Marsden Hospital (Surrey)
Sutton, Other, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.